导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.48% | 2413/4773 |
| 近一周 | 0.84% | 1620/5465 |
| 近一月 | -8.57% | 4802/5421 |
| 近一季 | 13.28% | 175/5231 |
| 近半年 | 2.81% | 1009/4920 |
| 近一年 | -13.67% | 3623/4394 |
| 近两年 | 33.53% | 2172/2954 |
| 近三年 | 0.61% | 1921/2253 |
| 成立以来 | 131.34% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.07% 2661/4961 |
-1.89% 3373/5312 |
- - |
- - |
| 2025 | 14.54% 2604/4813 |
5.26% 804/3635 |
3.39% 1025/4076 |
21.41% 1800/4524 |
-13.31% 4289/4813 |
| 2024 | -12.21% 2366/3463 |
-12.27% 2454/2808 |
-10.78% 2471/3014 |
21.37% 589/3129 |
-7.58% 2779/3463 |
| 2023 | -8.68% 1046/2656 |
0.94% 1668/2280 |
-5.02% 1344/2385 |
-1.20% 493/2515 |
-3.59% 732/2655 |
| 2022 | -21.91% 1055/2207 |
-14.31% 934/1919 |
-0.87% 1657/2016 |
-17.84% 1649/2113 |
11.90% 136/2208 |
| 2021 | 2.91% 626/1822 |
-4.64% 879/1255 |
25.11% 98/1330 |
-12.82% 1315/1466 |
-1.07% 1306/1822 |
| 2020 | 68.98% 81/1250 |
9.44% 22/1028 |
27.87% 123/1067 |
9.92% 604/1164 |
9.86% 621/1184 |
| 2019 | 33.23% 436/1092 |
26.32% 414/754 |
-8.96% 624/804 |
10.70% 47/850 |
4.66% 789/918 |
| 2018 | -23.78% 301/834 |
- - |
- - |
- - |
-20.70% 670/691 |
| 2017 | 25.99% 106/714 |
- - |
- - |
- - |
- - |
| 2016 | -11.69% 294/605 |
- - |
- - |
- - |
- - |
| 2015 | 47.96% 22/575 |
- - |
- - |
- - |
- - |
| 2014 | 7.09% 218/237 |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 华夏医药ETF VS. 长安沪深300非周期A(740101) |